phosphorylcholine has been researched along with Leishmaniasis, Mucocutaneous in 21 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Leishmaniasis, Mucocutaneous: A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil." | 2.90 | A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. ( Barroso, DH; Freire, GSM; Gomes, CM; Martins, SS; Motta, JOCD; Paula, CDR; Pereira, LIA; Porto, C; Sampaio, RNR; Silva, JSFE, 2019) |
| "Miltefosine was safe and relatively well tolerated and cure rate was higher than antimony." | 2.76 | Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. ( Chrusciak Talhari, C; Chrusciak-Talhari, A; da Silva, RM; de Oliveira Penna, G; Dietze, R; Gadelha Yamashita, EP; Lima Machado, PR; Talhari, S, 2011) |
| "Treatment with meglumine antimoniate had to be interrupted in six patients, with QTc prolongation the reason for the interruption in three patients." | 1.39 | Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. ( Blum, JA; Hatz, C; Mosimann, V; Neumayr, A, 2013) |
| "Miltefosine is an option for treating Old World leishmaniasis (Leishmania infantum) and immunodeficiency should be considered in patients with recurrent leishmaniasis." | 1.39 | Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome. ( Arnold, A; Blum, J; Holbro, A; Neumayr, A; Stoeckle, M; Weisser, M, 2013) |
| "Mucocutaneous leishmaniasis is a serious preventable complication of cutaneous leishmaniasis." | 1.35 | [Mucosal complication of cutaneous leishmaniasis]. ( Figueroa, RA; Miranda, MC; Prager, M; Zea, DF, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Crone, CG | 1 |
| Helleberg, M | 1 |
| Zanelli, G | 1 |
| Rossetti, B | 1 |
| Gagliardini, R | 1 |
| Paglicci, L | 1 |
| Tordini, G | 1 |
| Miracco, C | 1 |
| Aversa, S | 1 |
| Zammarchi, L | 1 |
| Di Muccio, T | 1 |
| Gramiccia, M | 1 |
| Montagnani, F | 1 |
| Murray, HW | 1 |
| Eiras, DP | 1 |
| Kirkman, LA | 1 |
| Chai, RL | 1 |
| Caplivski, D | 1 |
| Calvopina, M | 1 |
| Jijon, S | 1 |
| Serrano, E | 1 |
| Kato, H | 1 |
| Pinart, M | 1 |
| Rueda, JR | 1 |
| Romero, GA | 1 |
| Pinzón-Flórez, CE | 1 |
| Osorio-Arango, K | 1 |
| Silveira Maia-Elkhoury, AN | 1 |
| Reveiz, L | 1 |
| Elias, VM | 1 |
| Tweed, JA | 1 |
| Nieto-Meneses, R | 1 |
| Castillo, R | 1 |
| Hernández-Campos, A | 1 |
| Maldonado-Rangel, A | 1 |
| Matius-Ruiz, JB | 1 |
| Trejo-Soto, PJ | 1 |
| Nogueda-Torres, B | 1 |
| Dea-Ayuela, MA | 1 |
| Bolás-Fernández, F | 1 |
| Méndez-Cuesta, C | 1 |
| Yépez-Mulia, L | 1 |
| Sampaio, RNR | 1 |
| Silva, JSFE | 1 |
| Paula, CDR | 1 |
| Porto, C | 1 |
| Motta, JOCD | 1 |
| Pereira, LIA | 1 |
| Martins, SS | 1 |
| Barroso, DH | 1 |
| Freire, GSM | 1 |
| Gomes, CM | 1 |
| Mosimann, V | 1 |
| Neumayr, A | 2 |
| Hatz, C | 1 |
| Blum, JA | 1 |
| Stoeckle, M | 1 |
| Holbro, A | 1 |
| Arnold, A | 1 |
| Weisser, M | 1 |
| Blum, J | 1 |
| Garcia Bustos, MF | 1 |
| Barrio, A | 2 |
| Parodi, C | 1 |
| Beckar, J | 1 |
| Moreno, S | 1 |
| Basombrio, MA | 2 |
| Monge-Maillo, B | 1 |
| López-Vélez, R | 1 |
| Joob, B | 1 |
| Wiwanitkit, V | 1 |
| Bustos, MF | 1 |
| Kevric, I | 1 |
| Cappel, MA | 1 |
| Keeling, JH | 1 |
| Bezerra-Souza, A | 1 |
| Yamamoto, ES | 1 |
| Laurenti, MD | 1 |
| Ribeiro, SP | 1 |
| Passero, LF | 1 |
| Soto, J | 2 |
| Rea, J | 1 |
| Valderrama, M | 1 |
| Toledo, J | 2 |
| Valda, L | 2 |
| Ardiles, J | 2 |
| Berman, J | 2 |
| Zea, DF | 1 |
| Prager, M | 1 |
| Figueroa, RA | 1 |
| Miranda, MC | 1 |
| Chrusciak-Talhari, A | 1 |
| Dietze, R | 1 |
| Chrusciak Talhari, C | 1 |
| da Silva, RM | 1 |
| Gadelha Yamashita, EP | 1 |
| de Oliveira Penna, G | 1 |
| Lima Machado, PR | 1 |
| Talhari, S | 1 |
| Richter, J | 1 |
| Hanus, I | 1 |
| Häussinger, D | 1 |
| Löscher, T | 1 |
| Harms, G | 1 |
| Balderrama, M | 1 |
| Rea, I | 1 |
| Parra, R | 1 |
| Soto, P | 1 |
| Gomez, A | 1 |
| Molleda, F | 1 |
| Fuentelsaz, C | 1 |
| Anders, G | 1 |
| Sindermann, H | 1 |
| Engel, J | 1 |
| Tuon, FF | 1 |
| Amato, VS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL[NCT02193022] | Phase 3 | 80 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phosphorylcholine and Leishmaniasis, Mucocutaneous
| Article | Year |
|---|---|
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hypert | 2020 |
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Topics: Administration, Oral; Africa, Eastern; Antiprotozoal Agents; Bangladesh; Coinfection; Drug Therapy, | 2015 |
New World and Old World Leishmania Infections: A Practical Review.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations | 2015 |
5 trials available for phosphorylcholine and Leishmaniasis, Mucocutaneous
| Article | Year |
|---|---|
A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Mid | 2019 |
[Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Comparative Effectiveness Research; Female; Humans; I | 2014 |
Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.
Topics: Adult; Antiprotozoal Agents; Bolivia; Drug Administration Schedule; Female; Humans; Leishmaniasis, M | 2009 |
Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Leis | 2011 |
Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Female; Humans; Leishmania braziliensis; | 2007 |
13 other studies available for phosphorylcholine and Leishmaniasis, Mucocutaneous
| Article | Year |
|---|---|
Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Communicable Diseases, Imported; Ear; Humans; Leishma | 2020 |
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management.
Topics: Coinfection; HIV Infections; Humans; Leishmaniasis, Mucocutaneous; Male; Middle Aged; Phosphorylchol | 2019 |
Case Report: Mucosal Leishmaniasis in New York City.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Mucocuta | 2020 |
Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by
Topics: Aged, 80 and over; Antiprotozoal Agents; Cytochromes b; Dysphonia; Humans; Leishmania guyanensis; Le | 2020 |
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Topics: Amino Acid Sequence; Amphotericin B; Animals; Antiprotozoal Agents; Arginase; Benzimidazoles; Cell L | 2018 |
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; H | 2013 |
Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Topics: Administration, Oral; Aged; Antiprotozoal Agents; Histocytochemistry; Humans; Immunocompromised Host | 2013 |
[Miltefosine or meglumine antimoniate in leishmaniasis].
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Meglumine; Organometallic | 2015 |
[More about miltefosine in the treatment of mucosal leishmaniasis].
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Meglumine; Organometallic | 2015 |
The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Benzylamines; Drug Repositioning; Female; Leishman | 2016 |
[Mucosal complication of cutaneous leishmaniasis].
Topics: Aged; Anemia; Antiprotozoal Agents; Contraindications; Eyelid Diseases; Humans; Hypertension; Kidney | 2009 |
Mucosal Leishmania infantum infection.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Esophagus; Europe; Female; Humans; Leishmania inf | 2011 |
Mucosal leishmaniasis and miltefosine.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania; Leishmaniasis, Mucocutaneous; Phosphorylcholine | 2007 |